Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Label Statements Experimental Study, 11788-11789 [2011-4740]
Download as PDF
11788
Federal Register / Vol. 76, No. 42 / Thursday, March 3, 2011 / Notices
Dated: February 25, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–4741 Filed 3–2–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0098]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Infant Formula
Label Statements Experimental Study
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
a study entitled ‘‘Infant Formula Label
Statements Experimental Study.’’
DATES: Submit either electronic or
written comments on the collection of
information by May 2, 2011.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
srobinson on DSKHWCL6B1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:47 Mar 02, 2011
Jkt 223001
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes Agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal Agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Infant Formula Label Statements
Experimental Study—(OMB Control
Number 0910–NEW)
FDA is planning to conduct an
experimental study about certain types
of label statements on infant formula,
such as those that are either structure
function claims or similar to such
claims. An example of the type of
statements that are of interest is:
‘‘Supports brain and eye development.’’
The Infant Formula Label Statements
Experimental Study will collect
information from four groups: Pregnant
women, mothers of infants less than 12
months old, mothers of children older
than 1 year but younger than 5 years
old, and women of childbearing age
who do not have a child younger than
5 years. The purpose of the study is to
assess women’s understanding of and
response to various statements on infant
formula labels. The study results will be
used to help the Agency to understand
the role that certain types of statements
on infant formula labels have in
influencing formula choice.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
The data will be collected over the
Internet from a sample of 5,000 adult
women selected from an online
consumer panel. Participants will be
randomly assigned to an experimental
condition. The study will show
participants one of five explanations of
the regulatory, scientific, or marketing
context (or none of these) of infant
formula marketing in the United States
and will ask them to compare two sets
of two experimental infant formula
labels. One label will always be a
control label with no statement similar
to a structure function claim. The other
label will include one of the statements
of interest to the study. The study will
focus on purchase choice, perceived
similarity of the formula to breast milk,
and perceived likelihood that the
formula has certain health benefits. In
addition, information about certain
covariates will be collected, depending
on the group the participant is in.
Covariate information will include, as
appropriate, month of pregnancy, plans
for feeding the infant, number of
children, age of youngest child, whether
the youngest child was fed infant
formula, whether the youngest child
was ever breast fed, whether the mother
bought infant formula for her youngest
child, priorities used to select the
formula purchased, and attitudes about
the differences between breast milk and
formula. Participation in the study is
voluntary.
Approximately 10,000 women will be
screened. We estimate that it will take
a respondent 20 seconds (0.0055 hours)
to complete the screening questions, for
a total of 55 hours. A pretest will be
conducted with 150 participants. We
estimate that it will take a respondent
15 minutes (0.25 hours) to complete the
experiment and 10 minutes (0.167
hours) to complete debriefing questions
for the pretest, for a total of 25 minutes
(0.42 hours) per respondent and a total
of 63 hours for the pretest. Five
thousand (5,000) adult women will
complete the experiment. We estimate
that it will take a respondent 15 minutes
(0.25 hours) to complete the entire
experiment, for a total of 1,250 hours.
Thus, the total estimated burden is
1,368 hours. FDA’s burden estimate is
based on prior experience with
consumer experiments that are similar
to this proposed experiment.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\03MRN1.SGM
03MRN1
11789
Federal Register / Vol. 76, No. 42 / Thursday, March 3, 2011 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Portion of study
Annual
frequency per
response
Total annual
responses
Hours per
response
Total hours
Screener ...............................................................................
Pretest ..................................................................................
Experiment ...........................................................................
10,000
150
5,000
1
1
1
10,000
150
5,000
0.0055
0.42
0.25
55
63
1,250
Total ..............................................................................
........................
........................
........................
........................
1,368
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: February 25, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
Dated: February 16, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–4740 Filed 3–2–11; 8:45 am]
BILLING CODE 4160–01–P
[FR Doc. 2011–4738 Filed 3–2–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
A copy of the supporting statement for
this information collection is available
on the Internet at https://
www.reginfo.gov/public/do/PRAMain.
Dated: February 23, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–4739 Filed 3–2–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2006–N–0238] (formerly
2006N–0062)
Food and Drug Administration
[Docket No. FDA–2010–N–0344]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Testing Communications on Medical
Devices and Radiation-Emitting
Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
AGENCY:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Testing Communications on Medical
Devices and Radiation-Emitting
Products’’ has been approved by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of October 18, 2010 (75
FR 63838), the Agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0678. The
approval expires on January 31, 2014. A
copy of the supporting statement for this
information collection is available on
srobinson on DSKHWCL6B1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:47 Mar 02, 2011
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Expanded Access to Investigational
Drugs for Treatment Use
Jkt 223001
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Expanded Access to Investigational
Drugs for Treatment Use’’ has been
approved by the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400B, Rockville, MD 20850, 301–
796–3792,
Elizabeth.Berbakos@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of December 14, 2006
(71 FR 75147), the Agency announced
that the proposed information collection
had been submitted to OMB for review
and clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0653. The
approval expires on December 31, 2011.
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
[Docket No. FDA–2010–N–0478]
Albert Poet: Debarment Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (the FD&C Act)
permanently debarring Albert Poet, MD
from providing services in any capacity
to a person that has an approved or
pending drug product application. We
base this order on a finding that Dr. Poet
was convicted of felonies under Federal
law for conduct relating to the
regulation of a drug product under the
FD&C Act. Dr. Poet was given notice of
the proposed permanent debarment and
an opportunity to request a hearing
within the timeframe prescribed by
regulation. Dr. Poet failed to respond.
Dr. Poet’s failure to respond constitutes
a waiver of his right to a hearing
concerning this action.
DATES: This order is effective March 3,
2011.
ADDRESSES: Submit applications for
special termination of debarment to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Kenny Shade, Division of Compliance
Policy (HFC–230), Office of
Enforcement, Office of Regulatory
SUMMARY:
E:\FR\FM\03MRN1.SGM
03MRN1
Agencies
[Federal Register Volume 76, Number 42 (Thursday, March 3, 2011)]
[Notices]
[Pages 11788-11789]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-4740]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0098]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Infant Formula Label Statements Experimental Study
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on a study entitled ``Infant Formula Label
Statements Experimental Study.''
DATES: Submit either electronic or written comments on the collection
of information by May 2, 2011.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Infant Formula Label Statements Experimental Study--(OMB Control Number
0910-NEW)
FDA is planning to conduct an experimental study about certain
types of label statements on infant formula, such as those that are
either structure function claims or similar to such claims. An example
of the type of statements that are of interest is: ``Supports brain and
eye development.'' The Infant Formula Label Statements Experimental
Study will collect information from four groups: Pregnant women,
mothers of infants less than 12 months old, mothers of children older
than 1 year but younger than 5 years old, and women of childbearing age
who do not have a child younger than 5 years. The purpose of the study
is to assess women's understanding of and response to various
statements on infant formula labels. The study results will be used to
help the Agency to understand the role that certain types of statements
on infant formula labels have in influencing formula choice.
The data will be collected over the Internet from a sample of 5,000
adult women selected from an online consumer panel. Participants will
be randomly assigned to an experimental condition. The study will show
participants one of five explanations of the regulatory, scientific, or
marketing context (or none of these) of infant formula marketing in the
United States and will ask them to compare two sets of two experimental
infant formula labels. One label will always be a control label with no
statement similar to a structure function claim. The other label will
include one of the statements of interest to the study. The study will
focus on purchase choice, perceived similarity of the formula to breast
milk, and perceived likelihood that the formula has certain health
benefits. In addition, information about certain covariates will be
collected, depending on the group the participant is in. Covariate
information will include, as appropriate, month of pregnancy, plans for
feeding the infant, number of children, age of youngest child, whether
the youngest child was fed infant formula, whether the youngest child
was ever breast fed, whether the mother bought infant formula for her
youngest child, priorities used to select the formula purchased, and
attitudes about the differences between breast milk and formula.
Participation in the study is voluntary.
Approximately 10,000 women will be screened. We estimate that it
will take a respondent 20 seconds (0.0055 hours) to complete the
screening questions, for a total of 55 hours. A pretest will be
conducted with 150 participants. We estimate that it will take a
respondent 15 minutes (0.25 hours) to complete the experiment and 10
minutes (0.167 hours) to complete debriefing questions for the pretest,
for a total of 25 minutes (0.42 hours) per respondent and a total of 63
hours for the pretest. Five thousand (5,000) adult women will complete
the experiment. We estimate that it will take a respondent 15 minutes
(0.25 hours) to complete the entire experiment, for a total of 1,250
hours. Thus, the total estimated burden is 1,368 hours. FDA's burden
estimate is based on prior experience with consumer experiments that
are similar to this proposed experiment.
FDA estimates the burden of this collection of information as
follows:
[[Page 11789]]
Table 1--Estimated Annual Reporting Burden 1
----------------------------------------------------------------------------------------------------------------
Annual
Portion of study Number of frequency per Total annual Hours per Total hours
respondents response responses response
----------------------------------------------------------------------------------------------------------------
Screener......................... 10,000 1 10,000 0.0055 55
Pretest.......................... 150 1 150 0.42 63
Experiment....................... 5,000 1 5,000 0.25 1,250
------------------------------------------------------------------------------
Total........................ .............. .............. .............. ............. 1,368
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: February 25, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-4740 Filed 3-2-11; 8:45 am]
BILLING CODE 4160-01-P